Minireviews
Copyright ©The Author(s) 2022.
World J Gastrointest Surg. Jan 27, 2022; 14(1): 1-11
Published online Jan 27, 2022. doi: 10.4240/wjgs.v14.i1.1
Table 1 Studies assessing patient survival and disease-free survival after receiving a liver transplant for intrahepatic cholangiocarcinoma
Ref.
Study type
Number of LT patients
Overall survival (%)
DFS at 5-yr (%)
Comments
1-yr
3-yr
5-yr
No
iCCA
O’Grady et al[51], 1988Retrospective13381010-
Yokoyama et al[52], 1990Retrospective2500--
Meyer et al[53], 2000Retrospective Multicenter207724823-84% DFS at 25 mo
Shimoda et al[54], 2001Retrospective166239-35
Robles et al[55], 2004Retrospective multicenter23776542-2 yr DFS 35%
Sotiropoulos et al[56], 2009Retrospective10705033-
Fu et al[57], 2011Retrospective1150.550.53 yr DFS 51.9%
Hong et al[8], 2011Retrospective25-383233
Vallin et al[58], 2013Retrospective multicenter10806024-
Facciuto et al[29], 2015Retrospective7 iCCA; 9 iCCA + HCC; 16 iCCA-HCC71-5744
Vilchez et al[59], 2016Retrospective multicenter440795847-
Very early iCCA (< 2 cm)
Sapisochin et al[28], 2014Retrospective multicenter2778665136
Sapisochin et al[30], 2016Retrospective multicenter15 single < 2 cm; 33 multiple or > 2 cm93; 7984; 5065; 4582; 39
Locally advanced iCCA with sustained response to chemotherapy
Lunsford et al[5], 2018Prospective single-arm610083.383.350